Spots Global Cancer Trial Database for Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Official Title: A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors
Study ID: NCT01049893
Conditions
Interventions
Study Description
Brief Summary: AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe adverse events (AEs) related to the study drug.
Detailed Description: A phase 1 open-label, dose finding study of AC220 in patients with solid tumors.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute, Boston, Massachusetts, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Contact Details
Name: Guy Gammon, MB BS, MRCP
Affiliation: Interim Chief Medical Officer, Ambit Biosciences Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
